COMPANY

SomaLogic

Status: Acquired, now part of Illumina · How status works

Contact Opens the company's own website

Profile checked Oct 10, 2026

Keywords: Cardiovascular Risk Factor Cardiovascular Diseases Metabolic Syndrome

Timeline

Jun 13, 2017 Trial start —: Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk source ↗
2010-04 Trial start Not phased (device or behavioral study): Protandim and the Metabolic Syndrome source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03599531	Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk	Not listed	Completed	Jun 13, 2017	Oct 10, 2020 (actual)
NCT01125501	Protandim and the Metabolic Syndrome	Not phased (device or behavioral study)	Withdrawn	2010-04	2010-06 (estimated)

Annual award amounts. Total $302K.

Aug 15, 2005 NIH award 1R43AR052577-01 FY2005: $101,600 awarded for that fiscal year; activity R43 (SBIR); PI CHERONIS, JOHN C; recipient as written: SOMALOGIC, INC., BOULDER, CO. Proteomics-based Diagnosis and Management of RA source ↗
Jun 28, 2004 NIH award 1R43CA110407-01 FY2004: $100,166 awarded for that fiscal year; activity R43 (SBIR); PI CHERONIS, JOHN C; recipient as written: SOMALOGIC, INC., BOULDER, CO. Development and Application of Aptamer Arrays source ↗
Apr 15, 2004 NIH award 1R43CA108005-01 FY2004: $99,853 awarded for that fiscal year; activity R43 (SBIR); PI HEILIG, JOSEPH S; recipient as written: SOMALOGIC, INC., BOULDER, CO. Aptamer Development for Cancer Diagnosis and Manag source ↗